Global ROS1 initiative: A patient-researcher collaboration targeting ROS1 cancer

April 17, 2018, CU Anschutz Medical Campus
Global ROS1 initiative: A patient-researcher collaboration targeting ROS1 cancer
Stage IV lung cancer survivor and patient advocate, Janet Freeman-Daily helps to lead Global ROS1 Initiative, organizing patients across cancer types around the oncogene that causes them. Credit: University of Colorado Cancer Center

Cancer patients have often organized support and informational groups around their disease types. Now a presentation at the American Association for Cancer Research (AACR) Annual Meeting 2018 describes the first research-focused group of patients organized around the genetic mutation that creates their cancer, namely changes to the gene ROS1. While "ROS1 fusion" has primarily been studied in lung cancer, the Global ROS1 Initiative includes ROS1-positive (ROS1+) patients with melanoma and pancreatic cancer as well. And in addition to offering information and support, the group is helping to drive the direction of research aimed at cancers caused by this gene.

"We talked with researchers and we heard that one thing holding back research was lack of ROS1 models that researchers could use for experiments," says Janet Freeman-Daily. As patient advocate at the University of Colorado Cancer Center Lung Cancer Specialized Program of Research Excellence (SPORE), Freeman-Daily spoke with Robert C. Doebele, MD, PhD, CU Lung SPORE PI and Director of CU Cancer Center Thoracic Oncology Research Initiative, and in partnership, CU, the Global ROS1 Initiative and the Bonnie J. Addario Lung Cancer Foundation created a program in which could donate cancer tissue for use in establishing .

"We have already received four remote tumor samples and generated two new ROS1 cell lines from patients who never even had to travel to University of Colorado," says Doebele.

Members of the Global ROS1 Initiative have also been involved in an epidemiological survey with the goal of better understanding patient characteristics associated with ROS1 cancers. Results of this survey will be presented at AACR. Another project has surveyed the group to discover the percentage of ROS1 patients who have experienced brain metastases. An ongoing project hopes to discover if the sequence of treatments used against ROS1 cancer impacts outcomes.

"We have a larger number of patients in our group than on any single clinical trial, so we hope this will be an opportunity for researchers to learn about us and a way for us to learn more about our condition. We're working with clinicians and researchers to figure out how our group can best accelerate research," Freeman-Daily says.

The group represents a trend in oncology to move away from defining cancer by the site where it occurs and toward defining cancer by the genetic changes that create it. Following the model of the Global ROS1 Initiative are groups organized around ALK, EGFR and HER2, all of which have been found to cause multiple cancer types.

"This may be a more functional, precision medicine approach to certain types of cancer," says Robert. C. Doebele, MD, PhD. "More and more we're showing that cancers caused by ROS1 or many other genetic drivers may be treated with similar drugs no matter where the cancer lives in the body."

The group, which can be found at ROS1cancers.com ("Because I couldn't figure out how to make Wordpress give us a .org," says Freeman-Daily), includes over 200 ROS1+ patients across 20 countries.

"We provide support and education for each other, help find treatments and clinical trials, and talk about side effects. And we bring information we learn from our doctors back to the group," Freeman-Daily says.

Eventually, this innovative model may also bring treatments to the that would otherwise have been impossible.

Explore further: Two studies find resistance mechanisms in ALK+ and ROS1+ cancers

Related Stories

Two studies find resistance mechanisms in ALK+ and ROS1+ cancers

April 11, 2018
Targeted treatments have revolutionized care for lung cancer patients whose tumors harbor ALK or ROS1 alterations. Basically, cancers may use these genetic changes to drive their growth, but also become dependent on the action ...

Validation of an IHC screening tool for ROS1 gene rearrangements

May 11, 2016
Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, ...

Crizotinib treatment effective against ROS1-positive lung cancer

September 27, 2014
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine ...

Ros1 gene fusions found in 2.4% of Asian patients with lung adenocarcinoma, associated with young age at diagnosis

July 21, 2014
ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer (NSCLC), using multiplex reverse ...

Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer

December 17, 2013
A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some ...

NEJM reports positive results for larotrectinib against TRK-fusion cancer

February 22, 2018
In 2013, the labs of University of Colorado Cancer Center investigator Robert C. Doebele, MD, PhD, and Dana-Farber Cancer Institute investigator Pasi A. Jänne, MD, PhD reported in Nature Medicine the presence of TRK gene ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.